NASDAQ •
Healthcare •
Drug Manufacturers - General •
Quote as of 08/28/2026
Company Profile
IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,322.14 mln
Float681 mln
Earnings Date11/10/2026
EPS
0.77
Decent
P / E
9.99
Undervalued
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-2.62
Likely reliable
Relative Strength
42
/ 100
Slightly lagging
Debt / Equity
1.54
High leverage
Business Description
Founded in 1909 and based in Barcelona, Spain, Grifols is a global healthcare company best known for turning human plasma into life-saving medicines used to treat conditions ranging from immune disorders and liver disease to neurological and blood-related illnesses. The company also develops diagnostic tools and testing services that help hospitals and laboratories detect infectious diseases and ensure safe blood transfusions. Beyond plasma, Grifols supplies hospitals with intravenous fluids, clinical nutrition products, and automated systems that streamline hospital operations, while also providing biological materials to pharmaceutical and biotech firms for research and manufacturing purposes.
